Search Results

Updating results

Abortion care: topic engagement

We are listening to your views on this quality standard. Comments close 22 October 2019.

Quality standard In consultation

Nintedanib for treating progressive fibrosing interstitial lung disease [ID1599]: appraisal consultation

We are listening to your views on this technology appraisal guidance. Comments close 21 October 2019.

Technology appraisal guidance In consultation

Episcissors-60 for guided mediolateral episiotomy: draft guidance

We are listening to your views on this medical technologies guidance. Comments close 01 November 2019.

In consultation

Tinnitus: assessment and management: draft guidance consultation

We are listening to your views on this NICE guideline. Comments close 01 November 2019.

NICE guideline In consultation

Fetoscopic prenatal repair for open neural tube defects in the fetus: interventional procedure consultation

We are listening to your views on this interventional procedures guidance. Comments close 24 October 2019.

Interventional procedures guidance In consultation

Open prenatal repair for open neural tube defects in the fetus: interventional procedure consultation

We are listening to your views on this interventional procedures guidance. Comments close 24 October 2019.

Interventional procedures guidance In consultation

Joint replacement (primary): hip, knee and shoulder: draft guidance consultation

We are listening to your views on this NICE guideline. Comments close 26 November 2019.

NICE guideline In consultation

Specialist neonatal respiratory care for babies born preterm: quality standard consultation

We are listening to your views on this quality standard. Comments close 11 November 2019.

Quality standard In consultation

Acute kidney injury: prevention, detection and management (update): draft guidance consultation

We are listening to your views on this NICE guideline. Comments close 31 October 2019.

NICE guideline In consultation

Atezolizumab with nab-paclitaxel for treating PD L1-positive, triple-negative, advanced breast cancer [ID1522]: appraisal consultation

We are listening to your views on this technology appraisal guidance. Comments close 24 October 2019.

Technology appraisal guidance In consultation

Social work interventions for adults with complex needs, including, learning disabilities and mental health: draft scope consultation

We are listening to your views on this NICE guideline. Comments close 18 November 2019.

NICE guideline In consultation

Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617

Proposed [GID-TA10545] Expected publication date: 19 September 2020

Technology appraisal guidance Proposed

Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]

Proposed [GID-TA10544] Expected publication date: TBC

Technology appraisal guidance Proposed

Filgotinib for treating moderate to severe rheumatoid arthritis ID1632

Proposed [GID-TA10541] Expected publication date: TBC

Technology appraisal guidance Proposed

End of life care (QS update)

Proposed [GID-QS10140] Expected publication date: TBC

Quality standard Proposed

Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

Proposed [GID-TA10542] Expected publication date: TBC

Technology appraisal guidance Proposed

Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

Proposed [GID-TA10522] Expected publication date: TBC

Technology appraisal guidance Proposed

Olaparib with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [ID1652]

Proposed [GID-TA10526] Expected publication date: TBC

Technology appraisal guidance Proposed

Ranibizumab for treating diabetic retinopathy [ID1592]

Proposed [GID-TA10521] Expected publication date: TBC

Technology appraisal guidance Proposed

Nintedanib for treating progressive fibrosing interstitial lung disease [ID1599]

Proposed [GID-TA10520] Expected publication date: TBC

Technology appraisal guidance Proposed

Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587

Proposed [GID-TA10519] Expected publication date: TBC

Technology appraisal guidance Proposed

Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604

Proposed [GID-TA10518] Expected publication date: TBC

Technology appraisal guidance Proposed

Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

Proposed [GID-TA10467] Expected publication date: TBC

Technology appraisal guidance Proposed

Eculizumab for treating relapsing neuromyelitis optica [ID1271]

Proposed [GID-TA10469] Expected publication date: TBC

Technology appraisal guidance Proposed

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683

Proposed [GID-TA10537] Expected publication date: 12 August 2020

Technology appraisal guidance Proposed

Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) ID1585

Proposed [GID-TA10538] Expected publication date: 12 August 2020

Technology appraisal guidance Proposed

Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)

Proposed [GID-TA10527] Expected publication date: TBC

Technology appraisal guidance Proposed

Abicipar pegol for treating wet age-related macular degeneration ID1533

Proposed [GID-TA10511] Expected publication date: TBC

Technology appraisal guidance Proposed

Brentuximab vedotin for untreated CD30-positive peripheral T-cell lymphoma ID1586

Proposed [GID-TA10514] Expected publication date: 12 August 2020

Technology appraisal guidance Proposed

Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429

Proposed [GID-TA10512] Expected publication date: TBC

Technology appraisal guidance Proposed

Midostaurin for treating advanced systemic mastocytosis ID1573

Proposed [GID-TA10503] Expected publication date: TBC

Technology appraisal guidance Proposed

Luspatercept for treating anaemia caused by myelodysplastic syndromes [ID1550]

Proposed [GID-TA10508] Expected publication date: TBC

Technology appraisal guidance Proposed

Angiotensin II for treating vasopressor-resistant hypotension caused by distributive shock ID1588

Proposed [GID-TA10507] Expected publication date: TBC

Technology appraisal guidance Proposed

Luspatercept for treating beta-thalassaemia ID1554

Proposed [GID-TA10506] Expected publication date: TBC

Technology appraisal guidance Proposed

Voxelotor for treating sickle cell disease [ID1403]

Proposed [GID-TA10505] Expected publication date: TBC

Technology appraisal guidance Proposed

Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

Proposed [GID-TA10458] Expected publication date: TBC

Technology appraisal guidance Proposed

Galcanezumab for preventing migraine [ID1372]

Proposed [GID-TA10454] Expected publication date: TBC

Technology appraisal guidance Proposed

Dupilumab for treating chronic rhinosinusitis with nasal polyps ID1179

Proposed [GID-TA10450] Expected publication date: TBC

Technology appraisal guidance Proposed

Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Proposed [GID-TA10453] Expected publication date: TBC

Technology appraisal guidance Proposed

Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]

Proposed [GID-TA10451] Expected publication date: 10 June 2020

Technology appraisal guidance Proposed

Dulaglutide for treating type 2 diabetes [ID1451]

Proposed [GID-TA10439] Expected publication date: TBC

Technology appraisal guidance Proposed

Semaglutide for treating type 2 diabetes (ID1450)

Proposed [GID-TA10438] Expected publication date: TBC

Technology appraisal guidance Proposed

Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

Proposed [GID-TA10431] Expected publication date: TBC

Technology appraisal guidance Proposed

Solriamfetol for treating excessive sleepiness caused by narcolepsy or obstructive sleep apnoea [ID1499]

Proposed [GID-TA10430] Expected publication date: TBC

Technology appraisal guidance Proposed

Depression in adults (update)

Proposed [GID-QS10057] Expected publication date: TBC

Quality standard Proposed

Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)

Proposed [GID-TA10426] Expected publication date: TBC

Technology appraisal guidance Proposed

Galcanezumab for preventing cluster headache [ID1212]

Proposed [GID-TA10425] Expected publication date: TBC

Technology appraisal guidance Proposed

Pitolisant hydrochloride for treating obstructive sleep apnoea ID1065

Proposed [GID-TA10385] Expected publication date: TBC

Technology appraisal guidance Proposed

Ravulizumab for treating paroxysmal nocturnal haemoglobinuria ID1457

Proposed [GID-HST10023] Expected publication date: TBC

Highly specialised technologies guidance Proposed

Rivaroxaban for treating chronic heart failure [ID1462]

Proposed [GID-TA10393] Expected publication date: TBC

Technology appraisal guidance Proposed